Navigation Links
Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the results of a new study indicating that HIV resistant to Protease Inhibitors (PI) may have reduced potential for the development of resistance to the HIV maturation inhibitor bevirimat in laboratory assays. The study, carried out by scientists in Dr. Eric Freed's group at the HIV Drug Resistance Program at the National Cancer Institute, Frederick, MD, in collaboration with Panacos, was presented at the Cold Spring Harbor Laboratory's (CSHL) Retrovirus Conference held May 22-27, 2007 in Cold Spring Harbor, NY.

While resistance to bevirimat has not yet been reported in clinical studies, bevirimat-resistant HIV can be generated in the laboratory, as is the case with other HIV drugs. In previous studies where HIV was grown for several weeks in cell culture in the presence of bevirimat at suboptimal concentrations, mutations conferring resistance to bevirimat were found exclusively at or near bevirimat's target, the capsid-SP1 cleavage site in the HIV Gag protein. Cleavage of capsid from SP1, the final step in viral maturation, is mediated by the viral protease enzyme. Bevirimat inhibits this cleavage step by interacting with the capsid-SP1 junction in Gag, suggesting that pre-existing PI resistance mutations may have an impact on the development of bevirimat resistance.

In the new study, wild-type HIV, as well as HIV bearing major mutations conferring PI resistance, were grown in cell culture in the presence of bevirimat at suboptimal concentrations. Bevirimat resistance developed after several weeks in both wild-type and PI-resistant HIV, but took more than twice as long to develop in the PI-resistant virus. The bevirimat resistance mutation that appeared in PI-resistant virus was located at th
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
(Date:7/30/2014)... July 30, 2014   Medical Equipment Solutions, Corp. ... awarded a Department of Defense (US Army) contract valued ... a mobile MRI diagnostic machine and technical support staffing. ... through the Small Business Administration (SBA), Medical Equipment is ... with the latest medical diagnostic equipment. The SBA 8-A ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
(Date:7/30/2014)... 30, 2014 The Restore My Blood Sugar ... high blood sugar levels can now find an amazingly successful ... new program was created by D. Chao and Andrew Forester ... for patients when it comes to normalizing blood sugar levels. ... is a secret to the cure of diabetes that all ...
(Date:7/30/2014)... Sugar Land, TX (PRWEB) July 30, 2014 ... pharmacy recently announced their plans to move to a new ... been announced, but they will be moving soon. , MedX ... 6302 W Broadway in Pearland, TX 77581. This is the ... than their current one and will include a drive thru ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... main drug to treat malaria, is now widespread ... ( P. falciparum ) parasites that cause ... genetic mutation in the parasites. However, a six-day ... standard three-day coursehas proved highly effective in treating ... in the New England Journal of Medicine ...
(Date:7/30/2014)... 2014 (HealthDay News) -- It can happen in an instant: ... or computer monitor and gets critically injured when the furniture ... child should look around their homes and imagine what could ... it is better than it becoming a reality," Dr. Alex ... in a college news release. Between 2009 and 2011, ...
Breaking Medicine News(10 mins):Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:MedX Pharmacy Relocates to New Facility 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Tip-Over Furniture Can Kill Kids 2
... , , HARRISBURG, Pa., Aug. ... across the state on the new Integrated Care Initiative, an effort ... and Medicaid issues. , , The new health ... create a single source for consumers to work with both agencies, ...
... , MINNEAPOLIS, Aug. 4 Court ordered Class ... USA, Inc. , et al. , court File No. 27-CV-01-18042 (action filed ... in Minnesota at any time before November 30, 2004, ... A class action lawsuit involving the marketing, advertising and promotion of Marlboro ...
... , , PALO ... launch of the PEAK((R)) PlasmaBlade TnA (Tonsil and Adenoid) tissue dissection ... (FDA). This new product is indicated for cutting and coagulation of ... removal of the tonsils and adenoids. , , ...
... , ATLANTA, Aug. 4 M2SYS ... today that GHG Corporation, an innovative time tracking software provider, ... software solution. , , Bio-SnapON(TM) allows GHG ... time tracking software, known as "eTSS," to eliminate buddy punching ...
... ... introduced a new technology offering including their new Scoreboard application. The ... a glance screen showing key business indicators updated in real-time. Data ... both. The Scoreboard will be available to clients that either license ...
... NEW YORK, Aug. 4 EVO Merchant Services, a leader ... the Ernst & Young Entrepreneur Of The Year ((R)) 2009 ... LLP, the award recognizes outstanding entrepreneurs who are building and leading ... of judges, and the award was presented at a gala event ...
Cached Medicine News:Health News:Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:PEAK Surgical Introduces PEAK PlasmaBlade(TM) TnA 2Health News:PEAK Surgical Introduces PEAK PlasmaBlade(TM) TnA 3Health News:M2SYS Biometric Software Solution Selected By GHG Corporation 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3Health News:EVO Merchant Services, CEO, Ray Sidhom Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Metro New York 2Health News:EVO Merchant Services, CEO, Ray Sidhom Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Metro New York 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: